BusinessArQule Provides Proprietary Pipeline Update for AKT InhibitorsBy Nasdaq OMXJan 28, 2016, 12:30 PM UTC
BusinessArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers SymposiumBy Nasdaq OMXJan 25, 2016, 12:31 PM UTC
BusinessArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers SymposiumBy Nasdaq OMXJan 25, 2016, 12:31 PM UTC
BusinessAREVA Med’s Second Production Facility on Schedule to Open in 2nd Quarter of 2016By Nasdaq OMXJan 21, 2016, 5:48 PM UTC
BusinessPeregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy ConferencesBy Nasdaq OMXJan 20, 2016, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other CancersBy Nasdaq OMXJan 11, 2016, 1:05 PM UTC
BusinessImmune Design Receives Orphan Drug Designation From the U.S. FDA for Complementary Components of CMB305By Nasdaq OMXJan 8, 2016, 8:42 PM UTC
BusinessPeregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With BavituximabBy Nasdaq OMXJan 6, 2016, 1:05 PM UTC
